Nikhil Lalwani, CEO and president of ANI Pharmaceuticals Inc. (NASDAQ: ANIP), sold 5,400 shares of common stock for a total of $401,220 under a Rule 10b5-1 trading plan initiated on May 26, 2026. The disposal was executed on August 25, 2026, at prices ranging from $73.58 to $74.61 per share, with a weighted average sales price of $74.30. Following the transaction, Lalwani retains 344,489 shares directly.
The company’s shares were trading at $74.56 at the time of the sale, near the midpoint of the 52-week range of $70.15 to $79.80. ANI Pharmaceuticals has a market capitalization of $1.62 billion and a trailing price-to-earnings ratio of 16.25.
ANI reported adjusted earnings per share of $2.21 for the second quarter of 2026, exceeding Wall Street’s estimate of $2.03, while revenue reached a record $266 million, topping the $262.14 million forecast. However, full-year guidance was reduced by $20 million to $25 million due to underperformance in the first half of the year, particularly for Cortrophin, a key product.
Analysts at Guggenheim maintained a Buy rating but trimmed the price target to $119 from $124, while Canaccord Genuity kept its Hold rating and lowered its target to $90 from $91, citing concerns over earnings and Cortrophin’s performance despite the revenue beat.
